Market Cap
$822.1M
AVTX
Avalo Therapeutics, Inc.
$14.99 ▲ +0.27%
Prev close $14.95Market cap$822.1M
ConsensusStrong Buy
12-mo target$44.08 (+194.1%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)26 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on AVTX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$724.3M
Inst. Activity
26 buys / 9 sells
Insider Activity
$0.00 buy / $2.7M sell
Insider Net $
-$2.7M
SEC Reports
12
Press Releases
4
Price chart 30d -21.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 other
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical s
Sep 16, 2026 Insider
Sullivan Christopher Ryan acquired via exercise 12,394 shares
Chief Financial Officer @ $9.88 ($122.5K)
Sep 16, 2026 Insider
Sullivan Christopher Ryan sold 12,394 shares
Chief Financial Officer @ $16.33 ($202.4K)
Sep 10, 2026 Insider
Aug 20, 2026 SEC Sullivan Christopher Ryan acquired via exercise 10,185 shares
Chief Financial Officer @ $8.04 ($81.9K)
CFO Christopher Ryan and CMO Mittie executed derivative exercises and sold shares totaling ~$819K in open-market sales o
CLUSTER — Impact 3/10
Avalo Therapeutics (AVTX) saw a massive institutional accumulation cluster in Q2 2026, with 11 buyers adding $180.7M in
INST-CLUSTER — Impact 6/10
Avalo Therapeutics reported Q2 2026 results with a net loss of $36.4M ($0.83/share), missing consensus of $0.66. The com
8-K — Impact 6/10
Jun 30, 2026 Inst.
FMR LLC — ADD
5,100,216 shares ($94.3M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 21 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 6, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Jun 16, 2026 | BTIG | REITERATE | Buy | 53% |
| Jun 12, 2026 | B of A Securities | INITIATE | Buy | 54% |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| May 14, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| May 14, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 11, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 10 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 10 | 10 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 8 | 10 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Price targets
Where 12 covering analysts think AVTX trades over the next 12 months.
$44.08 +194.1% upside Strong Buy
Current$14.99 Low$30.00 Median$40.50 High$60.00 12 analysts
$30.00$60.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 5 bullish, 1 bearish, 1 mixed, 5 neutral · avg impact 5.3/10.Plus 4 press releases.
NEUTRALCLUSTER3/10
CFO Christopher Ryan and CMO Mittie executed derivative exercises and sold shares totaling ~$819K in
Aug 20, 2026
BULLISHINST-CLUSTER6/10
Avalo Therapeutics (AVTX) saw a massive institutional accumulation cluster in Q2 2026, with 11 buyer
Aug 17, 2026
BULLISH8-K6/10
Avalo Therapeutics reported Q2 2026 results with a net loss of $36.4M ($0.83/share), missing consens
Aug 6, 2026
BULLISH8-K6/10
Avalo Therapeutics filed an 8-K announcing the advancement of AVTX-010, a long-acting next-generatio
Jun 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
other
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing
Sep 23, 2026
other
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing
Sep 23, 2026
short_volume
Short Volume: AVTX — 77.0% short (0.4M / 0.5M)
Short: 386,147 | Exempt: 0 | TRF Vol: 501,373 | Short Ratio: 77.0% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: AVTX — 69.3% short (0.4M / 0.6M)
Short: 387,043 | Exempt: 0 | TRF Vol: 558,163 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: AVTX — 62.1% short (0.3M / 0.5M)
Short: 324,824 | Exempt: 2,800 | TRF Vol: 523,244 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.56 | $-0.66–$-0.45 | 74.4% | -8.2% | 3↑ 2↓ | $0.0B | 7 |
| Next Q | $-0.51 | $-0.70–$-0.39 | -38.6% | -7.7% | 3↑ 2↓ | $0.0B | 7 |
| Current FY | $-2.72 | $-3.06–$-2.18 | 53.4% | -4.2% | 3↑ 4↓ | $0.0B | 7 |
| Next FY | $-2.74 | $-4.10–$-1.33 | -0.7% | -4.2% | 3↑ 4↓ | $0.0B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.560 | — |
| 7d ago | $-0.560 | — |
| 30d ago | $-0.517 | -0.043 |
| 60d ago | $-0.551 | -0.009 |
| 90d ago | $-0.562 | +0.002 |
Institutional ownership
Which big funds own AVTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $724.3M total value (39,192,014 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, STATE. Net buying activity: 26 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 5,100,216 | $94.3M | 13.0% | ADD +77.1% |
| BlackRock, Inc. | 4,365,553 | $80.7M | 11.1% | DOUBLED +1234.7% |
| STATE STREET CORP | 2,889,287 | $53.4M | 7.4% | DOUBLED +3932.3% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2,498,000 | $46.2M | 6.4% | DOUBLED +172.7% |
| Point72 Asset Management, L.P. | 2,387,026 | $44.1M | 6.1% | DOUBLED +160.6% |
| Avoro Capital Advisors LLC | 2,333,333 | $43.1M | 6.0% | ADD +65.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,264,246 | $41.8M | 5.8% | DOUBLED +214.6% |
| BANK OF AMERICA CORP /DE/ | 1,913,829 | $35.4M | 4.9% | DOUBLED +197.6% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,729,000 | $32.0M | 4.4% | DOUBLED +102.5% |
| ALLIANCEBERNSTEIN L.P. | 1,260,689 | $23.3M | 3.2% | NEW |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 2,879,481 | 5,100,216 | +77.1% | $94.3M |
| BlackRock, Inc. | DOUBLED | 327,082 | 4,365,553 | +1234.7% | $80.7M |
| STATE STREET CORP | DOUBLED | 71,654 | 2,889,287 | +3932.3% | $53.4M |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | DOUBLED | 916,000 | 2,498,000 | +172.7% | $46.2M |
| Point72 Asset Management, L.P. | DOUBLED | 916,142 | 2,387,026 | +160.6% | $44.1M |
| Avoro Capital Advisors LLC | ADD | 1,410,000 | 2,333,333 | +65.5% | $43.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | 719,694 | 2,264,246 | +214.6% | $41.8M |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 643,000 | 1,913,829 | +197.6% | $35.4M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 854,000 | 1,729,000 | +102.5% | $32.0M |
| ALLIANCEBERNSTEIN L.P. | NEW | — | 1,260,689 | — | $23.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$2.7M — $0.00 bought, $2.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 12,394 | $9.88 | $122.5K |
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 12,394 | $16.33 | $202.4K |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 10,185 | $8.04 | $81.9K |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 10,185 | $17.62 | $179.5K |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | SELL | 679 | $20.00 | $13.6K |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | EXERCISE | 679 | $8.04 | $5.5K |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | SELL | 31,031 | $20.05 | $622.3K |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 31,031 | $9.88 | $306.6K |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 37,945 | $9.88 | $374.9K |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | EXERCISE | 2,876 | $9.88 | $28.4K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AVTX.
Shares short
12,925,869
Settlement Sep 15, 2026
Change vs prior
+4.3%
Semi-monthly cycle
Days to cover
13.2
At avg daily volume
Of shares outstanding
≈24.1%
Estimate — not % of float
All AVTX filing & press-release reports (16)
- CLUSTER reportAug 20, 2026
- INST-CLUSTER reportAug 17, 2026
- 8-K reportAug 6, 2026
- 8-K reportJun 16, 2026
- PRESS-RELEASE reportJun 16, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 13, 2026
- CLUSTER reportMay 11, 2026
- PRESS-RELEASE reportMay 6, 2026
- 424B5 reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- DEFA14A reportApr 10, 2026
- CLUSTER reportApr 8, 2026
- CLUSTER reportApr 3, 2026
- PRESS-RELEASE reportMar 23, 2026